Biotechnology firm Biocon has entered into an agreement with the US-based Optimer Pharmaceuticals Inc for manufacturing antibiotic drug fidaxomicin, which is used in treatment of colon infection.
Its partnership with Optimer is recognition of Biocon's capabilities as an R&D partner as well as an acknowledgment of our global manufacturing facilities. The long-term agreement with Biocon is an important step in establishing a stable supply of fidaxomicin. For the past five years, Biocon has been an important partner in our fidaxomicin development programme.
The drug is used in treating CDI, which is caused by clostridium difficile a spore-forming bacterium that can cause serious infection of the colon by multiplying and producing toxins resulting in inflammation, severe diarrhea and, in serious cases, death.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: